Literature DB >> 33689159

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19.

Vivian Glück1, Sonja Grobecker1, Leonid Tydykov1, Bernd Salzberger2, Thomas Glück3, Tanja Weidlich3, Manuela Bertok3, Christine Gottwald3, Jürgen J Wenzel1, André Gessner1,4, Barbara Schmidt1,4, David Peterhoff5.   

Abstract

OBJECTIVE: To follow serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2 spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune response with symptoms, demographic parameters and severity of disease.
METHODS: Anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time points during the 30-week follow-up. COVID-19-specific symptoms were assessed with standardized questionnaires.
RESULTS: 95% of the participants mounted an IgG response with only modest decline after week 12. IgG-type antibodies were still detectable in almost 90% of the subjects at 30 weeks. IgA and IgM responses were less robust and antibody titers decreased more rapidly. At 30 weeks, only 25% still had detectable IgA-type and none had IgM-type antibodies. Higher age and higher disease severity were independently associated with higher IgG antibody levels, albeit with wide variations.
CONCLUSION: Serological immune responses after COVID-19 show considerable inter-individual variability, but show an association with increasing age and higher severity of disease. IgG-type anti-SARS-CoV-2 antibodies remain positive in 90% of the individuals 30 weeks after onset of symptoms.
© 2021. The Author(s).

Entities:  

Keywords:  Antibody titer; COVID-19; ELISA; SARS-CoV-2; Serological immune response; Severity of disease

Mesh:

Substances:

Year:  2021        PMID: 33689159      PMCID: PMC7944246          DOI: 10.1007/s15010-021-01598-6

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  33 in total

1.  Follow-up of adults with noncritical COVID-19 two months after symptom onset.

Authors:  Claudia Carvalho-Schneider; Emeline Laurent; Adrien Lemaignen; Emilie Beaufils; Céline Bourbao-Tournois; Saïd Laribi; Thomas Flament; Nicole Ferreira-Maldent; Franck Bruyère; Karl Stefic; Catherine Gaudy-Graffin; Leslie Grammatico-Guillon; Louis Bernard
Journal:  Clin Microbiol Infect       Date:  2020-10-05       Impact factor: 8.067

2.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Authors:  Jennifer M Dan; Jose Mateus; Yu Kato; Kathryn M Hastie; Esther Dawen Yu; Caterina E Faliti; Alba Grifoni; Sydney I Ramirez; Sonya Haupt; April Frazier; Catherine Nakao; Vamseedhar Rayaprolu; Stephen A Rawlings; Bjoern Peters; Florian Krammer; Viviana Simon; Erica Ollmann Saphire; Davey M Smith; Daniela Weiskopf; Alessandro Sette; Shane Crotty
Journal:  Science       Date:  2021-01-06       Impact factor: 47.728

3.  Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.

Authors:  Baweleta Isho; Kento T Abe; Michelle Zuo; Alainna J Jamal; Bhavisha Rathod; Jenny H Wang; Zhijie Li; Gary Chao; Olga L Rojas; Yeo Myong Bang; Annie Pu; Natasha Christie-Holmes; Christian Gervais; Derek Ceccarelli; Payman Samavarchi-Tehrani; Furkan Guvenc; Patrick Budylowski; Angel Li; Aimee Paterson; Feng Yun Yue; Lina M Marin; Lauren Caldwell; Jeffrey L Wrana; Karen Colwill; Frank Sicheri; Samira Mubareka; Scott D Gray-Owen; Steven J Drews; Walter L Siqueira; Miriam Barrios-Rodiles; Mario Ostrowski; James M Rini; Yves Durocher; Allison J McGeer; Jennifer L Gommerman; Anne-Claude Gingras
Journal:  Sci Immunol       Date:  2020-10-08

4.  Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case.

Authors:  Guosheng Gao; Zhe Zhu; Lingyan Fan; Shuyuan Ye; Zuoan Huang; Qiaoyun Shi; Yedan Sun; Qifa Song
Journal:  Infection       Date:  2020-07-28       Impact factor: 7.455

5.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

6.  Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals.

Authors:  Etienne Brochot; Baptiste Demey; Antoine Touzé; Sandrine Belouzard; Jean Dubuisson; Jean-Luc Schmit; Gilles Duverlie; Catherine Francois; Sandrine Castelain; Francois Helle
Journal:  Front Microbiol       Date:  2020-10-19       Impact factor: 5.640

7.  A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.

Authors:  Barbara Schmidt; Ralf Wagner; David Peterhoff; Vivian Glück; Matthias Vogel; Philipp Schuster; Anja Schütz; Philip Neubert; Veruschka Albert; Stefanie Frisch; Mara Kiessling; Philip Pervan; Maren Werner; Nicole Ritter; Leon Babl; Maria Deichner; Frank Hanses; Matthias Lubnow; Thomas Müller; Dirk Lunz; Florian Hitzenbichler; Franz Audebert; Viola Hähnel; Robert Offner; Martina Müller; Stephan Schmid; Ralph Burkhardt; Thomas Glück; Michael Koller; Hans Helmut Niller; Bernhard Graf; Bernd Salzberger; Jürgen J Wenzel; Jonathan Jantsch; André Gessner
Journal:  Infection       Date:  2020-08-21       Impact factor: 7.455

8.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.

Authors:  Ania Wajnberg; Fatima Amanat; Adolfo Firpo; Deena R Altman; Mark J Bailey; Mayce Mansour; Meagan McMahon; Philip Meade; Damodara Rao Mendu; Kimberly Muellers; Daniel Stadlbauer; Kimberly Stone; Shirin Strohmeier; Viviana Simon; Judith Aberg; David L Reich; Florian Krammer; Carlos Cordon-Cardo
Journal:  Science       Date:  2020-10-28       Impact factor: 47.728

9.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.

Authors:  Carolyn Rydyznski Moderbacher; Sydney I Ramirez; Jennifer M Dan; Alba Grifoni; Kathryn M Hastie; Daniela Weiskopf; Simon Belanger; Robert K Abbott; Christina Kim; Jinyong Choi; Yu Kato; Eleanor G Crotty; Cheryl Kim; Stephen A Rawlings; Jose Mateus; Long Ping Victor Tse; April Frazier; Ralph Baric; Bjoern Peters; Jason Greenbaum; Erica Ollmann Saphire; Davey M Smith; Alessandro Sette; Shane Crotty
Journal:  Cell       Date:  2020-09-16       Impact factor: 66.850

10.  First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)".

Authors:  Christoph Spinner; Jörg Janne Vehreschild; Carolin E M Jakob; Stefan Borgmann; Fazilet Duygu; Uta Behrends; Martin Hower; Uta Merle; Anette Friedrichs; Lukas Tometten; Frank Hanses; Norma Jung; Siegbert Rieg; Kai Wille; Beate Grüner; Hartwig Klinker; Nicole Gersbacher-Runge; Kerstin Hellwig; Lukas Eberwein; Sebastian Dolff; Dominic Rauschning; Michael von Bergwelt-Baildon; Julia Lanznaster; Richard Strauß; Janina Trauth; Katja de With; Maria Ruethrich; Catherina Lueck; Jacob Nattermann; Lene Tscharntke; Lisa Pilgram; Sandra Fuhrmann; Annika Classen; Melanie Stecher; Maximilian Schons
Journal:  Infection       Date:  2020-10-01       Impact factor: 7.455

View more
  20 in total

1.  Severe acquired haemophilia associated with asymptomatic SARS-CoV-2 infection.

Authors:  Kevin Y Wang; Pratik Shah; Dennis T Roarke; Shams A Shakil
Journal:  BMJ Case Rep       Date:  2021-07-20

2.  Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review.

Authors:  Destin Groff; Ashley Sun; Anna E Ssentongo; Djibril M Ba; Nicholas Parsons; Govinda R Poudel; Alain Lekoubou; John S Oh; Jessica E Ericson; Paddy Ssentongo; Vernon M Chinchilli
Journal:  JAMA Netw Open       Date:  2021-10-01

3.  Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.

Authors:  Emelie Marklund; Susannah Leach; Kristina Nyström; Anna Lundgren; Jan-Åke Liljeqvist; Staffan Nilsson; Aylin Yilmaz; Lars-Magnus Andersson; Mats Bemark; Magnus Gisslén
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

4.  A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.

Authors:  Anna Solastie; Camilla Virta; Anu Haveri; Nina Ekström; Anu Kantele; Simo Miettinen; Johanna Lempainen; Pinja Jalkanen; Laura Kakkola; Timothée Dub; Ilkka Julkunen; Merit Melin
Journal:  Microbiol Spectr       Date:  2021-11-17

5.  Longitudinal SARS-CoV-2 Seroconversion Course and Antibody Levels by Blood Groups in Convalescent Plasma Donors in Turkey.

Authors:  Aziz Karaca; Mustafa Nuri Guncikan; Nazlı Nadire Sozmen; Gizem Gokce Karadag; Mustafa Yilmaz; Kerem Kinik; Fatma Meric Yilmaz
Journal:  Medeni Med J       Date:  2021-09-30

6.  Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.

Authors:  Gloria Griffante; Shikha Chandel; Daniela Ferrante; Valeria Caneparo; Daniela Capello; Valentina Bettio; Cinzia Borgogna; Chiara Aleni; Salvatore Esposito; Andrea Sarro; Alessandra Vasile; Marco Comba; Tommaso Testa; Gianmarco Cotrupi; Marco De Andrea; Sara Bortoluzzi; Marisa Gariglio
Journal:  Viruses       Date:  2021-11-12       Impact factor: 5.048

7.  Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals.

Authors:  Anna-Lena Mader; Leonid Tydykov; Vivian Glück; Manuela Bertok; Tanja Weidlich; Christine Gottwald; Alexa Stefl; Matthias Vogel; Annelie Plentz; Josef Köstler; Bernd Salzberger; Jürgen J Wenzel; Hans Helmut Niller; Jonathan Jantsch; Ralf Wagner; Barbara Schmidt; Thomas Glück; André Gessner; David Peterhoff
Journal:  iScience       Date:  2022-03-14

8.  Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.

Authors:  Niko Kohmer; Cornelia Rühl; Sandra Ciesek; Holger F Rabenau
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

9.  Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection.

Authors:  Ariel Israel; Yotam Shenhar; Ilan Green; Eugene Merzon; Avivit Golan-Cohen; Alejandro A Schäffer; Eytan Ruppin; Shlomo Vinker; Eli Magen
Journal:  Vaccines (Basel)       Date:  2021-12-31

10.  Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents.

Authors:  Carolina Garrido; Jillian H Hurst; Cynthia G Lorang; Jhoanna N Aquino; Javier Rodriguez; Trevor S Pfeiffer; Tulika Singh; Eleanor C Semmes; Debra J Lugo; Alexandre T Rotta; Nicholas A Turner; Thomas W Burke; Micah T McClain; Elizabeth A Petzold; Sallie R Permar; M Anthony Moody; Christopher W Woods; Matthew S Kelly; Genevieve G Fouda
Journal:  JCI Insight       Date:  2021-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.